Leede Financial Brokers Cut Earnings Estimates for TSE:TH

Theratechnologies Inc. (TSE:TH) – Stock analysts at Leede Financial decreased their FY2025 earnings per share estimates for Theratechnologies in a note issued to investors on Wednesday, February 26th. Leede Financial analyst D. Loe now expects that the company will earn $0.09 per share for the year, down from their previous estimate of $0.10. The consensus estimate for Theratechnologies’ current full-year earnings is $0.03 per share. Leede Financial also issued estimates for Theratechnologies’ FY2025 earnings at $0.09 EPS, FY2026 earnings at $0.21 EPS and FY2027 earnings at $0.33 EPS.

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Theratechnologies Trading Up 5.3 %

TSE:TH opened at C$2.37 on Friday. Theratechnologies has a 52-week low of C$1.59 and a 52-week high of C$3.13. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of -293.92. The stock has a fifty day simple moving average of C$2.50 and a 200-day simple moving average of C$2.03. The company has a market capitalization of C$75.62 million, a PE ratio of -26.83, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.